ACS Medicinal Chemistry Letters

Letter

Subscriber access provided by TULANE UNIVERSITY

Use of a conformational switching mechanism to modulate exposed polarity: discovery of CCR2 antagonist BMS-741672

Michael G. Yang, Zili Xiao, Robert Joseph Cherney, Andrew Joseph Tebben, Douglas G. Batt, Gregory D. Brown, Jing Chen, Mary Ellen Cvijic, Marta Dabros, John V. Duncia, Michael A.
Galella, Daniel S Gardner, Purnima Khandelwal, Soo S Ko, Mary F Malley, Ruowei Mo, Jian Pang, Anne V Rose, Joseph B Santella, Hong Shi, Anurag S. Srivastava, Sarah C. Traeger, Bei Wang, Songmei Xu, Rulin Zhao, Joel C Barrish, Sandhya Mandlekar, Qihong Zhao, and Percy H Carter

ACS Med. Chem. Lett., Just Accepted Manuscript • DOI: 10.1021/acsmedchemlett.8b00439 • Publication Date (Web): 16 Jan 2019

Downloaded from http://pubs.acs.org on January 17, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Use of a conformational switching mechanism to modulate exposed polarity: discovery of CCR2 antagonist BMS-741672

Michael G. Yang, Zili Xiao, Robert J. Cherney, Andrew J. Tebben, Douglas G. Batt, Gregory D.
Brown, Jing Chen, Mary Ellen Cvijic, Marta Dabros, John V. Duncia, Michael Galella, Daniel S.
Gardner, Purnima Khandelwal, Soo S. Ko, Mary F. Malley, Ruowei Mo, Jian Pang, Anne V. Rose,
Joseph B. Santella, III, Hong Shi, Anurag Srivastava, Sarah C. Traeger, Bei Wang, Songmei Xu, Rulin
Zhao, Joel C. Barrish, Sandhya Mandlekar, Qihong Zhao and Percy H. Carter*

Bristol-Myers Squibb Company, Research & Development, Rt. 206 & Province Line Rd., Princeton, NJ 08543 (USA) *KEYWORDS chemokine, G protein-coupled receptor, conformational analysis, hydrogen bonding, oral bioavailability, ion channels.*

ABSTRACT: We encountered a dilemma in the course of studying a series of antagonists of the G-Protein Coupled Receptor CC Chemokine Receptor-2 (CCR2): compounds with polar C3 sidechains exhibited good ion channel selectivity but poor oral bioavailability, whereas compounds with lipophilic C3 sidechains exhibited good oral bioavailability in pre-clinical species but poor ion channel selectivity. Attempts to solve this through the direct modulation of physicochemical properties failed. However, the installation of a protonation-dependent conformational switching mechanism resolved the problem, as it enabled a highly selective and relatively polar molecule to access a small population of a conformer with lower polar surface area and higher membrane permeability. Optimization of the overall properties in this series yielded the CCR2 antagonist BMS-741672 (7), which embodied properties suitable for study in human clinical trials.

Drug discovery efforts are frequently characterized by challenges in obtaining compounds with the right combination of biological activity, off-target selectivity, and oral bioavailability. Our studies on a series of antagonists of the G-protein coupled receptor CCR2 have uncovered similar issues, as have many other programs at different institutions.^{1,2,3} Although each research program is unique, general correlations between physicochemical properties and drug candidate attrition have now been posited.⁴ Herein we discovery of a protonation-dependent describe the conformational switching mechanism that enabled the discovery of small molecules with both sufficient polarity to engender selectivity and the ability to adopt a more hydrophobic conformation to facilitate oral bioavailability. This approach enabled us to identify a CCR2 antagonist suitable for clinical studies and may be valuable for other scientists engaged in drug design.

CCR2 is a G protein-coupled receptor that plays a central role in the biology of classical "inflammatory" monocytes,⁵ mediating their emigration from the bone marrow and extravasation into inflamed tissues,⁶ wherein they differentiate into either monocyte-derived macrophages or monocytederived dendritic cells.⁷ Unlike their tissue-resident counterparts, CCR2⁺ macrophages promote inflammation through the secretion of cytokines and other inflammatory mediators.⁸ Consistent with this paradigm, gene knockout or knockdown studies have implicated CCR2 as playing a contributory role in numerous pre-clinical analogs of human diseases, including models of diabetes, atherosclerosis, autoimmune disease, and cancer.^{9,10,11,12} Our own efforts focused on the development of small molecule CCR2 antagonists, as highlighted by the two representative molecules below (Figure 1).



Figure 1. Compounds with similar CCR2 binding affinity but strikingly different overall profiles.

Compound 1, a potent CCR2/CCR5 dual antagonist, exhibited good oral bioavailability in the rat, as well as mouse, monkey, and dog.¹³ Although it was selective over hERG, as assessed by a >2,000-fold difference in CCR2 binding IC₅₀ (0.7 nM) and its hERG patch clamp IC₅₀ (1,800 nM), our subsequent detailed *in vivo* electrophysiology studies suggested that the molecule did

ACS Paragon Plus Environment





Cmpd	Х	CCR2 Binding	CCR5 Binding	hERG p.c.	PAMPA perm.	HLM
		(IC ₅₀ , nM)	(IC ₅₀ , nM)	(%Inhibition)	(nm/sec)	(rate, %rem.)
2	CH ₂ SO ₂ CH ₃	1.8 ± 0.8 (12)	1636 ± 760 (6)	4%, 10 μM	94 ± 58 (10)	0.00, 100%
3	NHSO ₂ CH ₃	1.9 ± 0.8 (10)	3469 ± 906 (3)	45%, 10 μΜ	593 (1)	0.05, 85%
4	N(Me)SO ₂ CH ₃	1.4 ± 0.6 (8)	1570 (1)	7%, 10 μM	65 ± 43 (3)	0.00, 100%
1	CH ₂ CH ₂ CH ₃	0.7 ± 0.3 (23)	2.4 ± 1.0 (200)	83%, 10 μM	529 ± 157 (9)	0.00, 100%
5	CH ₂ SO ₂ CH ₃	0.9 ± 0.3 (5)	190 (1)	16%, 30 µM	14 (1)	0.00, 99%
6	NHSO ₂ CH ₃	0.4 ± 0.20 (5)	287 ± 196 (2)	74%, 10 μM	394 ± 340 (2)	0.13, 58%
7	NHC(O)CH ₃	1.1 ± 0.7 (18)	780^{b}	33%, 10 µM	443 ± 114 (8)	0.01, 95%

^{*a*}Both binding values are reported as mean \pm SD (n). CCR2 binding was measured through blockade of MCP-1 (CCL2) binding to human peripheral blood mononuclear cells. CCR5 binding was assessed through antagonism of MIP-1 β binding to HT1080 cells stably expressing CCR5. Inhibition of hERG was assessed in a manual patch clamp assay, and is expressed as %inhibition at a single test concentration. PAMPA permeability (reported in nanometers/second) was assessed at RT and a pH of 7.4; data are reported as the average of a single experiment performed in triplicate (standard deviation <10% mean) or as the average of multiple runs (with standard deviation across those experiments). The metabolism in human liver microsomes at a substrate concentration of 3 μ M is shown as rate of disappearance (nmol/min/mg) and % parent remaining (10 min). ^{*b*}The CCR5 binding for this lead compound 7 was also assessed in native T-cells, wherein it exhibited a binding value of 23.6 ± 12 nM

not have a sufficient safety margin for advancement. In contrast, the CCR2-selective antagonist 2 exhibited high selectivity over hERG, which was confirmed in vivo, but did not have good oral bioavailability in the rat, mouse, or monkey.¹⁴ In order to improve oral bioavailability and ion channel selectivity in our tri-substituted cyclohexyl series, we engaged in extensive structure-activity relationship (SAR) studies of the exocyclic amine, cyclohexyl C3-sidechain, and benzamide region.¹⁵ Generally speaking, our efforts were aimed at introducing polarity into analogs of 1 and hydrophobicity into analogs of 2, in an attempt to find a compound with more balanced properties.¹⁶ A particularly noteworthy result emerged from the replacement of the proximal methylene of sulfone 2 with an amine to give sulfonamide 3 (Table 1). Although the sulfonamide exhibited similar CCR2 and CCR5 binding affinities to the sulfone, it had lower hERG selectivity and, to our surprise, higher PAMPA permeability, making it closer to the n-propyl series (cf. 1 - 3, Table 1). In contrast, the N-methyl sulfonamide 4, which was ostensibly more lipophilic than 3, had good hERG selectivity and poor PAMPA permeability, like the polar sulfone 2. The differences in permeability and metabolism between compounds 2 - 4 were confirmed *in vivo*. Relative to sulfone 2, sulfonamide 3 exhibited higher oral bioavailability in mouse (35 vs 16 F%) despite having higher clearance (258 vs. 70 mL/min/kg). In contrast, N-Me sulfonamide 4 exhibited poor mouse pharmacokinetics, like 2 (IV Cl = 67 vs. 70 mL/min/kg; PO F% 11 vs. 16).

The replacement of the sulfone sidechain with a sulfonamide was also studied in the context of the quinazoline capping group. The sulfonamide 6 retained the CCR2-selectivity of the sulfone 5, but exhibited improved PAMPA

permeability (Table 1). It was surprising to us that sulfonamide **6** had a PAMPA Pc that was similar to that of the *n*-propyl analog **1**, despite the marked difference in their polarity (cLogP of 1.0 vs. 4.7). We synthesized a range of compounds that contained different sidechain motifs and studied the PAMPA permeability of those that exhibited appropriate CCR2 affinity. A selection of these compounds is shown in Figure 2. A clear structure-property relationship was evident: those compounds that contained an -N(H)R motif as the linking unit on the C3-sidechain (Fig. 2, blue data series) exhibited higher PAMPA values than those that did not (Fig. 2, red data series). This trend held largely independent of cLogP, although there were exceptions at the high and low end of the cLogP range (as expected).

Relative to their sulfone counterparts, both sulfonamides exhibited worse metabolic stability (Table 1, *cf.* **3** and **2**; **6** and **5**). Intriguingly, the N-Me analog **4**, which had a new metabolic soft spot, exhibited superior metabolic stability to the parent **3** in both human and rodent liver microsomes. Analysis of the in vitro metabolites indicated that the dominant metabolic pathway for **2** and **3** was identical: oxidative demethylation of the tertiary amine. Quite remarkably, the simple acetamide did not exhibit this metabolic

54

55

56

57 58 59



Figure 2. Shown is a plot of cLogP vs. PAMPA (normalized to reference standard 1) for a series of analogs from the trisubstituted cyclohexyl series. All of these compounds are analogs of 1/5/6, in that they contain the N-isopropyl, N-methyl-amine motif, the γ -lactam linker, and the quinazoline capping group.

liability, and proved to be one of the most effective replacements of the sulfonamide that we identified in this survey. Indeed, acetamide 7 retained potent CCR2 binding activity while exhibiting high hERG selectivity, PAMPA permeability, and *in vitro* metabolic stability (Table 1).¹⁷ Furthermore, compound 7 (BMS-741672) had improved mouse oral bioavailability (28 F%) and IV half-life (38 mL/min/kg) relative to **2**, **3**, and **4**, so we advanced it into additional studies (see below and ref. 17).

The optimized first generation synthesis of compound 7 is shown below in Scheme 1. Our previously described¹⁸ key intermediate **S.1** was subjected to a four step sequence¹⁹ to install the γ -lactam. Hydrolytic opening of **S.2** to give acid **S.3** was followed by coupling with ammonia to yield the carboxamide, which was subjected to Hoffman rearrangement (including trapping with acetic anhydride) to yield acetamide **S.4**. Conversion of **S.4** to the key compound BMS-741672 (7) followed a simple sequence consisting of acid-mediated Boc removal, double reductive amination, hydrogenolysis of the Cbz, and coupling with 4-chloro-6-trifluoromethylquinazoline. This route served to provide material for all pre-clinical studies, and was an important precursor to our recently reported second generation route.²⁰

In the context of investigating the optimal formulation of compound 7 to support clinical trials, we conducted a number of small molecule crystal studies with various salt forms. The conformation of the molecule depended on whether the compound was studied as a salt or free base. Specifically, when studied as an amine salt, we found that the lactam of 7 was axial while the acetamide and amine moieties were equatorially disposed (Fig. 3A, orange, Lactam Axial DiEquatorial, "LADE"). This conformation matched that of the receptor-bound,²¹ protonated 1 (Fig. 3C, blue), as well as salt of compound the TFA (Fig. 3C,

Scheme 1. Synthesis of BMS-741672 (7)^a



^a Reagents & Conditions: (a) 1 atm H₂, Pd/C, EtOAc; (b) Cbz-Met-OH, TBTU, iPr_2NEt , MeCN; (c) MeI, 48 h; (d) Cs₂CO₃, DMSO; (e) LiOH, THF/H₂O; (f) EDC, HOBt, CH₂Cl₂, then NH₃; (g) PhI(OAC)₂, MeCN/H₂O, then Ac₂O, iPr_2NEt ; (h) TFA, CH₂Cl₂; (i) acetone, NaBH₃CN, MeOH; (j) CH₂O, NaB(OAC)₃H, CH₂Cl₂; (k) 1 atm H₂, Pd/C, MeOH; (l) 4-Cl,6-CF₃-quinazoline, iPr_2NEt , iPrOH.



Figure 3. X-ray crystal structures of compounds **1**, **6** and **7**. (A) The bis-benzenesulfonic acid (omitted for clarity) salt of **7** (orange) exists in the chair configuration with γ -lactam disposed axially. The free-base of **7** (blue) exists in the chair configuration with the γ -lactam disposed equatorially. (B) Hydrogen bonding network in the **7** free base crystal structure. (C) The X-ray structures of the free-base of **1** (red) and TFA (omitted for clarity) salt of **6** (orange) overlaid with the CCR2-bound conformation of the protonated form of **1** (blue) extracted from the **1**/CCR2 complex crystal structure (pdb id 5T1A). All exist in the LADE chair conformation. (D) Hydrogen bonding network in the **6** TFA salt crystal structure.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

57 58 59

60

orange; see also Fig. 3D). The free-base of compound **1** was also shown to exhibit this LADE conformation (Fig. 3C, red). However, the crystalline form of the free base of **7** displayed a very different conformation, in which the cyclohexyl chair flipped such that the lactam was equatorial, while the acetamide and amino moieties were diaxially disposed (Fig. 3A, blue, Lactam Equatorial DiAxial, "LEDA"). Note that the acetamide bridges the tertiary amine and quinazoline NH via intramolecular H-bonds in this LEDA conformation (Fig. 3B). The pH-dependent conformational switching of **7** that was observed in the solid state was further confirmed in solution studies via ¹H-NMR spectroscopy (see Supporting Information).

The aforementioned crystal structures were coupled with ab initio calculations to enable a detailed understanding of the protonation dependent conformational biases within these systems. When the tertiary amine is protonated, the LADE chair conformation is lower in energy for every substituent in the third position (Table 2, Protonated; see Supporting Information for additional details). However, in the free-base form, the conformational preferences vary depending on the nature of the C3-substituent. The polar moieties in compounds 6 (sulfonamide) and 7 (acetamide) are able to engage the hydrogen bonding network observed in the compound 7 freebase crystal structure (Fig. 3B). These hydrogen bonds stabilize the LEDA conformation and overcome the unfavorable steric clashes inherent to the diaxial disposition of the two substituents. Indeed, calculations predict the LEDA conformation to be favored by 4.8 and 5.4 kcal/mol for compounds 6 and 7, respectively (Table 2, Free Base). Compound 5 shows a smaller calculated bias (0.6 kcal/mol) toward the LEDA conformation because, while the sulfone still hydrogen bonds the aminoquinazoline NH, the hydrogen bond to the tertiary amine is not present in the structure. The *n*-propyl group in compound **1** is unable to stabilize the LEDA conformation through any hydrogen bonding and the calculated conformational preference is LADE in both the protonated and free base species.

The above observations led us to propose a model of pHdependent conformational flipping to enable oral bioavailability, as shown in Figure 4. The progression begins with the tertiary amine predominately in the protonated form²² within the slightly acidic to neutral environment of the intestinal lumen (measured pKa=9.5, calculated population 98%). In this state, compound 7 is predicted to be almost entirely LADE as it is calculated to be 1.9 kcal/mol lower in energy than LEDA (see Supporting Information for detailed discussion of the ab initio calculations). However, within the small non-protonated subpopulation, the conformational stabilities are reversed with the LEDA conformation being 5.4 kcal/mol lower in energy. Its relative stability arises from two intramolecular hydrogen bonds, which masks two hydrogen bond do
 Table 2. Ab initio calculated relative energies and polar surface areas.



	Proton	ated			Free Base						
	LEDA				LEDA						
Cpd	ΔE^{a}	PSA ^b	PSA ^b		ΔE^{a}	PSA ^b	PSA^b				
1	1.7	267	266		3.6	247	242				
5	0.9	270	310		-0.6	252	288				
6	1.5	270	299		-4.8	255	282				
7	1.9	272	282		-5.4	234	264				

 $^{a}\Delta E = E_{LEDA} - E_{LADE}$ (kcal/mol). Representative LEDA and LADE conformations for compound 1 are illustrated above the table. The minimized conformations for compounds 1, 5, 6 and 7 are shown in SI Figure 1. ^bPolar surface area, PSA (Å²), is computed from the 3D conformations.

nors, lowers PSA, and desolvates the acetamide moiety. The small relative concentrations of the non-protonated, LEDA form can readily enter the lipid environment, driving the equilibrium toward this species. The compound then exits the lipid environment to enter either the aqueous environment of the lumen or the bloodstream. Once the compound exits the membrane into the circulation, oral bioavailability has been secured. In this environment, the equilibrium population will again favor the protonated LADE conformation, which is the conformation required for CCR2 binding.²¹ In this conformation, the polar sidechain is exposed and the selectivity for the molecule relative to ion channels is therefore high. Thus, the model suggests that compound 7 largely exists in protonated LADE in aqueous environments, but that a small equilibrium population of unprotonated LEDA is sufficient to act as a shuttle between the intestine and the bloodstream by enabling 7 to enter the lipid environment and thereby traverse the intestinal wall.

Changes in pH and ion content have previously been shown to enable "molecular switching" in certain pre-disposed systems, including six-membered carbo- and heterocycles.^{23,24} Furthermore, intramolecular hydrogen-bonding is known to mask exposed polarity in peptides and can sometimes be correlated with enhanced membrane permeability and even oral bioavailability.^{25,26,27,28,29} The solution to our problem required that this masking was context dependent, so that the polar form of the molecule was the one predominantly available. Based on the structure-activity



Figure 4. Working model for the equilibrium populations of acetamide 7 in both high-dielectric aqueous and low-dielectric lipid environments. Percentages on the horizontal arrows are Boltzmann populations calculated from the relative ab initio conformational energies, denoted beneath each structure. The Boltzmann populations on the vertical arrows are calculated using the Henderson-Hasselbalch equation using an amine pKa of 9.5 and buffer pH of 7.3.

relationships relative to CCR2 binding, hERG functional activity, and membrane permeability, the conformational switching mechanism (Figure 4) appeared to remain intact within this trisubstituted cyclohexane series so long as three elements remained in place: a secondary or tertiary amine at C1, an amide or sulfonamide directly linked to C3, and the Friedinger lactam at C4. Modification of these groups (e.g. homologation of the acetamide, or replacement of the lactam with a glycinamide) disrupted the SAR trends. However, with these groups in place, optimized molecules for the inhibition of CCR2 could be obtained. Acetamide 7 (BMS-741672) was one such molecule. Specifically, BMS-741672 was found to have 51% oral bioavailability in rat with a $t_{1/2}$ of 5.1 h (IV), and 46% oral bioavailability in Cynomolgus monkey with a $t_{1/2}$ of 3.2 h (IV). It exhibited an IC₅₀ of 0.67 nM for the inhibition of monocyte chemotaxis in vitro, and was fully active in both monkey and hCCR2 knock-in mouse models of monocyte chemotaxis (see ref. 17). The compound proved to have a suitable safety margin for advancement, based on single-day tolerability studies (rat, monkey) and a 14-day toxicology study in the rat. Relative to our general concerns over hERG selectivity, it was notable that 7 did not show any effects on the QTc interval in telemetrized monkeys at a dose of 30 mg/kg. Taken together, the pre-clinical studies with BMS-741672 enabled its advancement into human clinical trials.

ASSOCIATED CONTENT

Supporting Information. Synthetic procedures and complete characterization data for the compounds described, including structural studies on different forms of compound **7**. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

* (P.H.C.) Tel.: 609-252-4144. E-mail: percy.carter@bms.com

Author Contributions

The manuscript was written through contributions of all authors.

Funding Sources

This work was funded by Bristol-Myers Squibb Company.

ACKNOWLEDGMENT

We acknowledge our many colleagues in the CCR2 Discovery Working Group, as well as the Department of Discovery Synthesis at the Biocon-BMS R&D Center (Bangalore, India). We also thank Dr. Nicholas A. Meanwell for helpful comments on the manuscript.

ABBREVIATIONS

CCR2, CC chemokine receptor 2; CCR5, CC chemokine receptor 5; LADE, Lactam Axial DiEquatorial, LEDA, Lactam Equatorial DiAxial.

REFERENCES

¹ Carter, P. H. Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012. *Expert Opin. Ther. Pat.* **2013**, *23* (5), 549 - 568.

² Struthers, M.; Pasternak, A. CCR2 antagonists. *Curr. Top. Med. Chem.* **2010**, *10* (13), 1278 – 1298.

³ Solari, R.; Pease, J. E.; Begg, M. "Chemokine receptors as therapeutic targets: why aren't there more drugs?" *Eur. J. Pharmacol.* **2015**, *746*, 363 – 367.

⁴ Waring, M. J.; Arrowsmith, J.; Leach, A. R.; Leeson, P. D.; Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S. D.; Wang, J.; Wallace, O.; Weir, A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nat. Rev. Drug Disc.* **2015**, *14* (7), 475 – 486.

⁵ Gordon, S.; Taylor, P. R. Monocyte and macrophage heterogeneity. *Nat. Rev. Immunol.* **2005**, *5* (12), 953 – 964.

⁶ Ingersoll, M. A.; Platt, A. M.; Potteaux, S.; Randolph, G. J. Monocyte trafficking in acute and chronic inflammation. *Trends Immunol.* **2011**; *32* (10), 470 – 477.

⁷ Ginhoux, F.; Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. *Nat. Rev. Immunol.* **2014**, *14* (6), 392 – 404.

⁸ Wynn, T. A.; Chawla, A.; Pollard, J. W. Macrophage biology in development, homeostasis, and disease. *Nature* **2013**, *496*, 445 – 455.

⁹ Kang, Y. S.; Cha, J. Jo.; Hyun, Y. Y.; Cha, D. R. Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of

1

2

3

4 5

6

7

8

9 10

11

12

13

14

15

16

17

18 19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55 56

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55 56

57 58 59

60

recent developments. *Expert Opin. Investigational Drugs* **2011**, *20* (6), 745 – 756.

¹⁰ Charo, I. F.; Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. *N. Engl. J. Med.* **2006**, *354* (6), 610–621.

¹¹ Feria, M.; Díaz-González, F. The CCR2 receptor as a therapeutic target. *Exp. Opin. Ther. Patents* **2006**, *16* (1), 49 – 57.

¹² Leuschner, F.; Dutta, P.; Gorbatov, R.; Novobrantseva, T. I.; Donahoe, J. S.; Courties, G.; Lee, K. M.; Kim, J. I.; Markmann, J. F.; Marinelli, B.; Panizzi, P.; Lee, W. W.; Iwamoto, Y.; Milstein, S.; Epstein-Barash, H.; Cantley, W.; Wong, J.; Cortez-Retamozo, V.; Newton, A.; Love, K.; Libby, P.; Pittet, M. J.; Swirski, F. K.; Koteliansky, V.; Langer, R.; Weissleder, R.; Anderson, D. G.; Nahrendorf, M. Therapeutic siRNA silencing in inflammatory monocytes in mice. *Nat. Biotechnol.* **2011**, *29* (11), 1005 – 1010.

¹³ Carter, P. H.; Brown, G. D.; Cherney, R. J.; Batt, D. G.; Chen, J.; Clark, C. M.; Cvijie, M. E.; Duncia, J. V.; Ko, S. S.; Mandlekar, S.; Mo, R.; Nelson, D. J.; Pang, J.; Rose, A. V.; Santella, J. B., 3rd; Tebben, A. J.; Traeger, S. C.; Xu, S.; Zhao, Q.; Barrish, J. C. Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5. *ACS Med. Chem. Lett.* **2015**, *6* (4), 439 – 44.

¹⁴ Cherney, R. J.; Mo, R.; Yang, M. G.; Xiao, Z.; Zhao, Q.; Mandlekar, S.; Cvijic, M. E.; Charo, I. F.; Barrish, J. C.; Decicco, C. P.; Carter, P. H. Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists. *Bioorg. Med. Chem. Lett.* **2014**, *24* (7), 1843 – 1845.

¹⁵ Carter, P. H.; Cherney, R. J.; Batt, D. G.; Duncia, John V.; Gardner, D. S.; Ko, S. S.; Srivastava, A. S.; Yang, M. G. Cyclic derivatives as modulators of chemokine receptor activity. PCT Int. Appl. WO 2005/021500; March 10, 2005.

¹⁶ Meanwell, N. A. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. *Chem. Res. Toxicol.* **2016**, *29* (4), 564 – 616.

¹⁷ Yang, M. G.; Cherney, R. J.; Eastgate, M. G.; Muslehiddinoglu, J.; Prasad, S. J.; Xiao, Z. Modulators of chemokine receptor activity, crystalline forms and process. PCT Int. Appl. WO 2008/014381; January 31, 2008.

¹⁸ Campbell, C. L.; Hassler, C.; Ko, S. S.; Voss, M. E.; Guaciaro, M. A.; Carter, P. H.; Cherney, R. J. Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxyl-methyl)cyclohexylcarbamate using an iodolactamization as the key step. *J. Org. Chem.* **2009**, *74* (16), 6368 – 6370.

¹⁹ Cherney, R. J.; Mo, R.; Meyer, D. T.; Voss, M. E.; Yang, M. G.; Santella, J. B., 3rd; Duncia, J. V.; Lo,Y. C.; Yang, G.; Miller, P. B.; Scherle, P. A.; Zhao, Q.; Mandlekar, S.; Cvijic, M. E.; Barrish, J. C.; Decicco, C. P.; Carter, P. H. gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. *Bioorg. Med. Chem. Lett.* **2010**, *20* (8), 2425 – 2430.

²⁰ Deerberg, J.; Prasad, S. J.; Sfouggatakis, C.; Eastgate, M. D.; Fan, Y.; Chidambaram, R.; Sharma, P.; Li, L; Schild, R.; Müslehiddinoğlu, J.; Chung, H-J.; Leung, S.; Rosso, V. Stereoselective Bulk Synthesis of CCR2 Antagonist BMS-741672: Assembly of an All-cis (S,R,R)-1,2,4-Triaminocyclohexane (TACH) Core via Sequential Heterogeneous Asymmetric Hydrogenations. *Organic Process Research & Development* **2016**, *20* (11), 1949 – 1966.

²¹ Zheng, Y.; Qin, L.; Zacarías, N. V.; de Vries, H.; Han, G. W.; Gustavsson, M., Dabros, M.; Zhao, C.; Cherney, R. J.; Carter, P.; Stamos, D.; Abagyan, R.; Cherezov, V.; Stevens, R. C.; IJzerman, A. P.; Heitman, L. H.; Tebben, A.; Kufareva, I.; Handel, T. M. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. *Nature* **2016**, *540*, 458 – 461.

²² In aqueous solution, BMS-741672 exists in equilibrium between

its diprotonated, monoprotonated and unprotonated states. Potentiometric titration reveals pKa values of 9.5 (tertiary amine) and 4.5 (quinazoline). Figure 4 considers only the equilibrium between monoprotonated and unprotonated states, in which the monoprotonated form (i.e. protonated tertiary amine) will dominate at physiological pH.

²³ Zheng, Y.; Liu, X.; Samoshina, N. M.; Samoshin, V. V.; Franz, A. H.; Guo, X. Fliposomes: trans-2-aminocyclohexanol-based amphiphiles as pH-sensitive conformational switches of liposome membrane - a structure-activity relationship study. *Chem. Phys. Lipids* **2018**, *210*, 129 – 141.

 24 Knipe, P. C.; Thompson, S.; Hamilton, A. D. Ion-mediated conformational switches. *Chem. Sci.* **2015**, *6* (3), 1630 – 1639.

²⁵ Thansandote, P.; Harris, R. M.; Dexter, H. L.; Simpson, G. L.; Pal, S.; Upton, R. J.; Valko, K. Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. *Bioorg Med Chem.* **2015**, *23* (2), 322 – 327.

²⁶ Hewitt, W. M.; Leung, S. S.; Pye, C. R.; Ponkey, A. R.; Bednarek, M.; Jacobson, M. P.; Lokey, R. S. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. *J. Am. Chem. Soc.* **2015**, *137* (2), 715 – 721.

²⁷ Shalaeva, M.; Caron, G.; Abramov, Y. A.; O'Connell, T. N.; Plummer, M. S.; Yalamanchi, G.; Farley, K. A.; Goetz, G. H.; Philippe, L.; Shapiro, M. J. Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using ΔlogP as a tool. J. Med. Chem. **2013**, *56* (12), 4870 – 4879.

²⁸ Rossi Sebastiano, M.; Doak, B. C.; Backlund, M.; Poongavanam, V.; Over, B.; Ermondi, G.; Caron, G.; Matsson, P.; Kihlberg, J. Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. *J. Med. Chem.* **2018**, *61* (9), 4189–4202.

²⁹ Nielsen, D. S.; Hoang, H. N.; Lohman, R. J.; Hill, T. A.; Lucke, A. J.; Craik, D. J.; Edmonds, D. J.; Griffith, D. A.; Rotter, C. J.; Ruggeri, R. B.; Price, D. A.; Liras, S.; Fairlie, D. P. Improving on nature: making a cyclic heptapeptide orally bioavailable. *Angew. Chem. Int. Ed. Engl.* **2014**, *53* (45), 12059 – 12063.

Use of a conformational switching mechanism to modulate exposed polarity: discovery of CCR2 antagonist BMS-741672

Michael G. Yang, Zili Xiao, Robert J. Cherney, Andrew J. Tebben, Douglas G. Batt, Gregory D. Brown, Jing Chen, Mary Ellen Cvijic, Marta Dabros, John V. Duncia, Michael Galella, Daniel S. Gardner, Purnima Khandelwal, Soo S. Ko, Mary F. Malley, Ruowei Mo, Jian Pang, Anne V. Rose, Joseph B. Santella, III, Hong Shi, Anurag Srivastava, Sarah Traeger, Bei Wang, Songmei Xu, Rulin Zhao, Joel C. Barrish, Sandhya Mandlekar, Qihong Zhao and Percy H. Carter*

Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 0843, United States.

